Scientists have laid the foundation of completely understanding the intricacies of distinct kidney cancer subtypes, which could lead to better treatments for the disease.
Van Andel Research Institute scientists conducted two studies. In one study led by Kyle Furge, Ph.D. and Aikseng Ooi, Ph.D., researchers provide a more complete understanding of the biology of Type 2 papillary renal cell carcinoma (PRCC2), an aggressive type of kidney cancer with no effective treatment, which lays the foundation for the development of effective treatment strategies.
Despite obvious morphological, genetic, and clinical differences, hereditary PRCC2 is thought to share similar pathway deregulation due to genetic mutation with its counterpart, clear cell renal cell carcinoma (CCRCC), a subtype that accounts for 75 percent of all kidney cancers and that, unlike PRCC2, responds favourably to drugs targeting vascular endothelial growth factor (VEGF), a signal protein produced by cells that stimulate blood vessel formation.
In another study led by Yan Ding, Ph.D. and Bin Tean Teh, Ph.D. researchers integrated gene expression profiling and RNAi screening data to identify genes involved in CCRCC development and progression.
In recent years, several molecularly targeted therapies such as sunitinib, sorafenib, and pazopanib, which target the receptor tyrosine kinases of VEGF have been approved for CCRCC.
Although these therapies significantly extend overall survival, nearly all patients with advanced CCRCC eventually succumb to the disease.
Gene set enrichment analysis indicated that cell-cycle-related genes, in particular PLK1, were associated with disease aggressiveness. Further, the association of PLK1 in both disease aggression and in vitro growth prompted researchers to examine the effects of a small-molecule inhibitor in CCRCC cell lines. Their findings highlight PLK1 as a promising potential therapeutic target for CCRCC.
The studies have been published in Cancer Cell and Cancer Research.